This year in Galveston, Texas, Silvia Pierangeli hosts the 13th International Congress on Antiphospholipid Antibodies. Twenty-six years after the first antiphospholipid syndrome meeting, the number of interested colleagues has multiplied, and the subject has become more scientifically understood. So also has the clinical picture. In this short contribution, I will highlight a number of clinical observations which may, or may not, contribute to our understanding of antiphospholipid syndrome.
Greco TP, Conti-Kelly AM, Greco T. Jr, et al. Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. Am J Clin Pathol2009; 132: 613-620.
2.
Urbanus RT, Siegerink B., Roest M., Rosendaal FR, de Groot PG, Algra A.Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case control study. Lancet Neurol2009; 8: 998-1005.
3.
Nair S., Khamashta MA, Hughes GRSyndrome X and Hughes Syndrome. Lupus2002 ; 11: 332.
4.
Hughes GRV.Migraine, memory loss and ‘multiple sclerosis’. Neurological features of the antiphospholipid (Hughes) syndrome . Postgrad Med J2003; 79: 81-83.
5.
Hughes GRV.Thrombosis abortion, cerebral disease, and the lupus anticoagulant. Brit Med J1983 ; 287: 1088-1099.
6.
Hughes GRV.The Prosser-White Oration 1983: Connective tissue disease and the skin. Clin Exp Dermatol1984; 9: 535-544.
Etiminan M., Takkouche B., Isarna FC, Samii A.Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ2005; 330: 63-66.